ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 608

Association of Discoid Lupus with Other Clinical Manifestations Among Patients with Systemic Lupus Erythematosus

Joseph F. Merola1, Christina Iversen2, Jose A. Gomez-Puerta2, Tabatha Norton2, Hsun Tsao2, Peter H. Schur2, Elena M. Massarotti2, Bonnie L. Bermas3 and Karen H. Costenbader2, 1Rheumatology, Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cutaneous lupus erythematosus, Nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Prior studies suggest that cutaneous discoid lupus (DLE) is a marker for less severe disease with a low frequency of nephritis and end-stage renal disease among SLE patients.  These past studies have not included diagnostic confirmation of DLE by expert dermatologists and did not adjust for medication use. We investigated associations of validated cases of DLE with other specific SLE manifestations in a large validated SLE Cohort.

Methods: Our academic hospital SLE registry contains data on 5,030 patients seen for potential SLE, 1970-2011. Inclusion criteria for this study were: definite SLE per treating rheumatologist and an SLE expert, 4/11 of 1997 ACR classification criteria for SLE, >2 visits and >3 months of follow-up, and a documented year of SLE diagnosis. The presence of DLE was validated by an expert dermatologist with review of multispecialty notes, pathology and digital images, when available. We collected SLE manifestations, medication and serologic data from review of electronic medical records. We tested for associations between DLE and each of the ACR SLE criteria, as well as end-stage renal disease (ESRD), using multivariable-adjusted logistic regression analyses.

Results: Of 1,043 SLE patients included, 92% were female and 51% White, 100% were ANA positive, 66% were anti-dsDNA positive. Mean age at diagnosis was 32 years (± 13) and mean duration of follow-up was 10 years (± 6.5). DLE (n=117) was significantly associated with the presence of photosensitivity, leukopenia and anti-Smith antibodies (Table). DLE was inversely associated with both arthritis and pleuritis. We found no significant associations between DLE and nephritis or ESRD.

Conclusion: In this large cohort of SLE patients, we have found an increased frequency of photosensitivity, leukopenia and anti-Smith antibodies among SLE patients with DLE and an inverse association of DLE with both pleuritis and arthritis. We did not observe the inverse associations of DLE with anti-dsDNA antibodies, lupus nephritis, or ESRD that have been noted in other studies. These findings have important implications for prognosis among patients with DLE and possibly for different underlying pathophysiologies of SLE subtypes.

 

Table. Associations between Discoid Lupus (n=117) and other ACR Criteria for SLE and End-Stage Renal Disease

SLE Manifestation

Number with DLE

Number without DLE

OR* (95% CI)

p-value

Anti-Smith        (n=246)

45

201

2.41 (1.58-3.69)

<0.01

Photosensitivity (n=434)

60

374

1.63 (1.09-2.44)

0.02

Leukopenia       (n=351)

50

301

1.55 (1.03-2.32)

0.04

Pleuritis            (n=380)

31

349

0.56 (0.36-0.87)

0.01

Arthritis            (n=817)

79

738

0.49 (0.31-0.76)

<0.01

No significant associations between discoid lupus and the following were found: malar rash, oral ulcers, pericarditis, proteinuria, casts, lupus nephritis, seizure, psychosis, anemia, lymphopenia, thrombocytopenia, anti-dsDNA, antiphospholipid antibodies, end-stage renal disease

*OR= odds ratio, adjusted:  Multivariable logistic regression analyses modeling the odds ratio of DLE associated with each SLE manifestation or laboratory finding separately, adjusted for age at diagnosis, sex, race/ethnicity, disease duration, ever medication use (azathioprine, cyclophosphamide, hydroxychloroquine, methotrexate, mycophenolate mofetil, systemic corticosteroids) 

 


Disclosure:

J. F. Merola,
None;

C. Iversen,
None;

J. A. Gomez-Puerta,
None;

T. Norton,
None;

H. Tsao,
None;

P. H. Schur,
None;

E. M. Massarotti,
None;

B. L. Bermas,
None;

K. H. Costenbader,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-discoid-lupus-with-other-clinical-manifestations-among-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology